Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects with Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment with RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

Next Previous
Trial Profile

A Phase III Multi-Center, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Clinical Trial in High-Risk Type 2 Diabetes Mellitus (T2DM) Subjects with Coronary Artery Disease (CAD) to Determine Whether Bromodomain Extraterminal Domain (BET) Inhibition Treatment with RVX000222 Increases the Time to Major Adverse Cardiovascular Events (MACE)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apabetalone (Primary) ; Atorvastatin; Rosuvastatin
  • Indications Acute coronary syndromes; Atherosclerosis; Cardiovascular disorders; Coronary artery disease; Ischaemic pain; Myocardial infarction; Myocardial ischaemia; Stroke; Unstable angina pectoris
  • Focus Registrational; Therapeutic Use
  • Acronyms BETonMACE
  • Sponsors Resverlogix Corporation

    • Most Recent Events

    • 22 Aug 2022 Results published in Resverlogix Corporation Media Release.
    • 22 Aug 2022 According to a Resverlogix Corporation media release, post-hoc analysis were presented in in the American Journal of Preventive Cardiology.
    • 17 Mar 2022 According to a Resverlogix Corporation media release, apabetalone received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) in Feb 2020 following the ground-breaking findings from this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top